Mikael Lindstam
Aptahem reports growing buzz around Apta-1
Malmö-based Aptahem recently released detailed plans of their upcoming phase II study with candidate Apta-1, set to prove its...
Aptahem's CEO on expectations for 2024
Earlier this fall, Aptahem completed the first part...
Aptahem's CEO on the promising analysis results
Aptahem announced in July that it has...
Aptahem comments on the paused phase I study
Aptahem is developing the drug candidate Apta-1 for the acute treatment of...
Aptahem takes the next step in the treatment of sepsis
Sepsis affects millions of people globally every year and...
Aptahem updates on operations and the issue
Aptahem makes progress in sepsis treatment with its drug candidate...
Further steps in Aptahem's Phase I study
At the end of December 2022, the biotechnology company Aptahem announced...
Aptahem's CEO on upcoming milestones
Aptahem has taken several steps forward in 2022...
Aptahem's CEO comments on the rights issue
Biotechnology company Aptahem's report for the third quarter of 2022 focused...
Newly formed research consortium granted SEK 12 million from the Knowledge Foundation
A new research project where both industry and academia partners...
BioStock Studio: Aptahem about upcoming phase I study
Malmö company Aptahem is getting closer to clinical studies with...
Aptahem about the latest news crop
Aptahem has communicated a number of positive news on...